Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

401 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of elsamitrucin in non-small cell lung cancer.
Goss G, Letendre F, Stewart D, Shepherd F, Schacter L, Hoogendoorn P, Eisenhauer E. Goss G, et al. Invest New Drugs. 1994;12(4):315-7. doi: 10.1007/BF00873046. Invest New Drugs. 1994. PMID: 7775132 Clinical Trial.
A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G, Hirte H, Miller WH Jr, Lorimer IA, Stewart D, Batist G, Parolin DA, Hanna P, Stafford S, Friedmann J, Walsh W, Mathews S, Douglas L, Seymour LK. Goss G, et al. Invest New Drugs. 2005 Mar;23(2):147-55. doi: 10.1007/s10637-005-5860-y. Invest New Drugs. 2005. PMID: 15744591 Clinical Trial.
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies.
Nehra J, Bradbury PA, Ellis PM, Laskin J, Kollmannsberger C, Hao D, Juergens RA, Goss G, Wheatley-Price P, Hotte SJ, Gelmon K, Tinker AV, Brown-Walker P, Gauthier I, Tu D, Song X, Khan A, Seymour L, Smoragiewicz M. Nehra J, et al. Among authors: goss g. Invest New Drugs. 2020 Oct;38(5):1442-1447. doi: 10.1007/s10637-020-00904-7. Epub 2020 Feb 4. Invest New Drugs. 2020. PMID: 32020438 Clinical Trial.
Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.
Leighl NB, Goss GD, Lopez PG, Burkes RL, Dancey JE, Rahim YH, Rudinskas LC, Pouliot JF, Rodgers A, Pond GR, Shepherd FA. Leighl NB, et al. Among authors: goss gd. Lung Cancer. 2006 Jun;52(3):327-32. doi: 10.1016/j.lungcan.2006.02.006. Epub 2006 Apr 4. Lung Cancer. 2006. PMID: 16597474 Clinical Trial.
Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens.
Goffin JR, Nicholas G, Mates M, Tu D, Chen E, Laurie SA, Juergens R, Robinson A, Goss G, Reaume M, Sun S, Christink K, Maize C, MacFarlan S, Sun X, Ritter H, Seymour L, Bradbury PA. Goffin JR, et al. Among authors: goss g. Invest New Drugs. 2019 Jun;37(3):498-506. doi: 10.1007/s10637-018-0680-z. Epub 2018 Oct 13. Invest New Drugs. 2019. PMID: 30317534 Clinical Trial.
Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115.
Maroun JA, Belanger K, Seymour L, Matthews S, Roach J, Dionne J, Soulieres D, Stewart D, Goel R, Charpentier D, Goss G, Tomiak E, Yau J, Jimeno J, Chiritescu G; National Cancer Institute of Canada Clinical Trials Group. Maroun JA, et al. Among authors: goss g. Ann Oncol. 2006 Sep;17(9):1371-8. doi: 10.1093/annonc/mdl165. Ann Oncol. 2006. PMID: 16966366 Free article. Clinical Trial.
401 results